Wire · opportunities
First Alzheimer's Blood Test for Adults with Cognitive Symptoms as Young as 40
◆ Sectors
Medtech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The FDA has cleared C2N Diagnostics' PrecivityAD2®, the first blood test for Alzheimer’s diagnosis in adults aged 40 and older with cognitive symptoms, providing a scalable and less invasive option than PET or cerebrospinal fluid testing.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can now target earlier-stage Alzheimer’s diagnosis without expensive scans. If your Medtech startup works on brain health or diagnostics, this clearance opens a new route for clinical adoption and reimbursement.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics
Medtechalzheimersblood-testFDA-clearancecognitive-impairmentdiagnostics